The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2018 | Current knowledge of the TP53 mutation and its role in CLL
TP53 is the single most commonly mutated gene in human malignancies, indicating it’s importance as an oncogene. Here, Jitka Malcikova, PhD, of the Masaryk University, Brno, Czech Republic, discusses our current knowledge of the TP53 mutation and its role in chronic lymphocytic leukemia (CLL). Dr Malcikova covers the methods being used to identify this mutation, and how our knowledge of the this mutation be used to inform the management of CLL in the clinic. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
